MarketCap
Facebook
X
Telegram
Exelixis EV/EBITDA Ratio | EXEL
Annual EV/EBITDA Ratio Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.2 | 15.8 | 37.5 | 25.2 | 18.4 | 13.2 | 13.1 | 14.8 | 52.1 | -8.69 | -10.1 | -3.01 | -7.82 | -5.84 | 9.23 | -12.6 | -4.23 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.1 | -12.6 | 9.42 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M |  USA |
 |
Amgen
AMGN
|
13.3 | $ 465.26 | 0.01 % | $ 250 B | USA |
 |
Biogen
BIIB
|
48.2 | $ 253.37 | -0.59 % | $ 37.1 B | USA |
 |
Edesa Biotech
EDSA
|
-0.0637 | $ 2.01 | -19.28 % | $ 11.4 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-15 | $ 15.12 | -0.72 % | $ 978 M | USA |
 |
Achieve Life Sciences
ACHV
|
552 | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-4.3 | $ 3.72 | -0.13 % | $ 236 M | USA |
 |
Immutep Limited
IMMP
|
-2.76 | $ 3.53 | -7.11 % | $ 5.14 B |  Australia |
 |
Iovance Biotherapeutics
IOVA
|
-0.135 | $ 8.09 | -1.04 % | $ 2.89 M | USA |
 |
Evogene Ltd.
EVGN
|
-0.106 | $ 0.37 | 28.7 % | $ 2.91 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
-17.1 | $ 3.71 | -2.5 % | $ 134 M | USA |
 |
Axsome Therapeutics
AXSM
|
-53.8 | $ 141.12 | 5.34 % | $ 7.02 B | USA |
 |
Keros Therapeutics
KROS
|
3.77 | $ 9.32 | 1.64 % | $ 347 M | USA |
 |
Champions Oncology
CSBR
|
392 | $ 4.85 | 0.21 % | $ 67.1 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-26.6 | $ 10.6 | -2.12 % | $ 303 M | USA |
|
Forte Biosciences
FBRX
|
-3.97 | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
-1.55 | $ 8.06 | 1.26 % | $ 1.25 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
-8.63 | $ 9.7 | 0.47 % | $ 456 M | USA |
 |
Grifols, S.A.
GRFS
|
13.7 | $ 8.74 | 0.63 % | $ 5.94 B |  Spain |
 |
Incyte Corporation
INCY
|
11.3 | $ 120.28 | -1.32 % | $ 23.5 B | USA |
 |
AC Immune SA
ACIU
|
-5.33 | $ 2.32 | -4.92 % | $ 234 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
-8.12 | $ 0.64 | 0.53 % | $ 38.4 M | USA |
 |
Aptose Biosciences
APTO
|
1.65 K | - | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
-0.315 | $ 9.47 | -2.17 % | $ 121 M | USA |
 |
AIM ImmunoTech
AIM
|
-1.18 | $ 0.14 | -11.15 % | $ 227 K | USA |
 |
Ascendis Pharma A/S
ASND
|
-102 | $ 256.21 | -1.4 % | $ 15.5 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
9.16 | $ 71.31 | 5.19 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-0.744 | $ 1.56 | 1.3 % | $ 48.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-2.4 | $ 1.31 | -0.76 % | $ 349 M |  Britain |
|
Monopar Therapeutics
MNPR
|
-20.5 | $ 71.42 | -3.16 % | $ 529 M | USA |
 |
BridgeBio Pharma
BBIO
|
-30 | $ 78.67 | 0.95 % | $ 15.1 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
8.17 | $ 7.53 | -1.38 % | $ 1.58 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
0.703 | $ 3.68 | -2.39 % | $ 255 M | Britain |
 |
Coherus BioSciences
CHRS
|
-1.86 | $ 0.64 | -21.66 % | $ 75 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-316 | $ 27.45 | 4.77 % | $ 3.49 B | USA |
 |
Cellectis S.A.
CLLS
|
-15.8 | $ 1.12 | -0.45 % | $ 112 M |  France |
 |
BeyondSpring
BYSI
|
-12.6 | $ 0.6 | -2.21 % | $ 24.7 M | USA |
 |
Alkermes plc
ALKS
|
19.2 | $ 46.48 | 0.67 % | $ 7.66 B |  Irlanda |
 |
Altimmune
ALT
|
-3.49 | $ 1.94 | -8.51 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
-2.37 | $ 0.79 | -0.77 % | $ 52.8 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-1.5 | $ 0.5 | -5.43 % | $ 5.53 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-0.593 | $ 9.41 | -0.84 % | $ 258 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
50 | $ 49.04 | -0.41 % | $ 6.56 B | USA |
 |
Atara Biotherapeutics
ATRA
|
3.26 | $ 8.18 | -0.73 % | $ 103 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
37 | $ 16.3 | -1.93 % | $ 2.19 B | Canada |
 |
Cullinan Management
CGEM
|
-3.52 | $ 11.34 | -3.32 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
-12.2 | $ 87.2 | -0.36 % | $ 21.1 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
38.8 | $ 24.47 | -0.97 % | $ 775 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-1.4 | $ 3.95 | 12.07 % | $ 52.6 M | USA |